Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

AI model may personalize liver cancer care after surgery

NCT ID NCT07562763

First seen May 04, 2026 · Last updated Jun 22, 2026 · Updated 11 times

Summary

This study analyzed data from 1005 liver cancer patients to see who benefits from a treatment called TACE after surgery. Using machine learning, researchers aimed to predict individual patient outcomes. The goal is to help doctors decide whether to recommend TACE or just monitor the patient.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • The First Affiliated Hospital of USTC

    Hefei, Anhu, 23000, China

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

transcatheter arterial chemoembolization (TACE)

What this could lead to

If successful, this could help doctors personalize treatment decisions for liver cancer patients after surgery, potentially improving outcomes.

What could go wrong

This is a retrospective analysis, not a controlled trial, so results may not apply to all patients. The model needs further validation before clinical use.

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.